MAPT and Alzheimer disease: Collectively, the available literature from different models of AD disease including Tau toxicity, genetic and pharmacologic inhibition of Trx system, and our current observation with Aβ42 model, indicate that LB1 degradation is a common event in these models, however, whether this is the cause or consequence of these changes remain unknown.